28
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      Call for Papers: Supportive Care - Essential for Modern Oncology

      Submit here before December 31, 2024

      About Oncology Research and Treatment: 2.0 Impact Factor I 3.2 CiteScore I 0.521 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      The Mode of Action of Vinca Alkaloids

      research-article
      , , ,
      Oncology
      S. Karger AG
      Vincristine, F-leurosine, Drug resistance, P388 leukemia, Cell membrane

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          P388 leukemia-bearing mice were given a single i.p. injection of [<sup>14</sup>C]-vincristine and the levels of radioactivity in the tumors and host tissues were determined as a function of time. The highest levels of radioactivity were found in the gallbladder followed by the tumor, spleen and liver, respectively. 24 h after drug administration the tumor contains 5.8% of the radioactivity detected in the tumor 1 h after drug administration. The tumor thus does not retain the alkaloid for a long period of time. At subcellular level tubulin was found to bind the highest amount of the alkaloid, followed by the fraction containing Golgi and plasma membranes. P388 tumor sensitive to vincristine (VCR) and formyl-leurosine (F-leu) incorporates three times more VCR and four times more F-leu than the resistant line of the same tumor. The different drug uptake as well as the different Vinca alkaloid binding capacity of membrane fractions of the sensitive and resistant P388 leukemias suggests that the composition and/or the structure of the cell membrane has changed in the resistant line. Vinca alkaloid-induced cell cycle changes were evaluated by cytophotometry. The cytotoxic effect of Vinca alkaloids does not correlate with their ability to arrest cells in metaphase. Multinuclear cells showing higher ploidy could be detected in the later phase of the treatment; these cells are the representatives of the surviving population. Selective killing of G<sub>1</sub> cells is supposed to be a possible way of the cytotoxic action of Vinca alkaloids.

          Related collections

          Author and article information

          Journal
          OCL
          Oncology
          10.1159/issn.0030-2414
          Oncology
          S. Karger AG
          978-3-8055-1588-7
          978-3-318-01589-8
          0030-2414
          1423-0232
          1980
          1980
          10 June 2009
          : 37
          : Suppl 1
          : 83-87
          Affiliations
          Research Institute of Oncopathology, Budapest
          Article
          225502 Oncology 1980;37:83–87
          10.1159/000225502
          7454202
          fd69c645-f61f-424f-8ae5-d06ab6000a71
          © 1980 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          History
          Page count
          Pages: 5
          Categories
          Developments of Cancer Chemotherapy

          Oncology & Radiotherapy,Pathology,Surgery,Obstetrics & Gynecology,Pharmacology & Pharmaceutical medicine,Hematology
          Vincristine,F-leurosine,Cell membrane,Drug resistance,P388 leukemia

          Comments

          Comment on this article